Beta Bionics (NASDAQ:BBNX) Price Target Raised to $20.00

Beta Bionics (NASDAQ:BBNX) had its price target hoisted by Bank of America from $18.00 to $20.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a neutral rating on the stock.

Several other research analysts also recently weighed in on BBNX. Robert W. Baird lifted their price target on shares of Beta Bionics from $14.00 to $16.00 and gave the stock a “neutral” rating in a research note on Tuesday. Weiss Ratings upgraded Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. The Goldman Sachs Group raised their target price on Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. William Blair initiated coverage on Beta Bionics in a research report on Friday, August 21st. They set a “market perform” rating on the stock. Finally, Truist Financial reissued a “buy” rating and set a $23.00 price target (up from $22.00) on shares of Beta Bionics in a report on Tuesday. Seven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $21.90.

Beta Bionics Stock Down 3.4%

Beta Bionics stock opened at $21.43 on Tuesday. The business has a 50-day simple moving average of $17.56 and a two-hundred day simple moving average of $13.99. The company has a market cap of $964.14 million, a P/E ratio of -12.99 and a beta of 3.37. Beta Bionics has a 52-week low of $8.80 and a 52-week high of $32.71.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. The company had revenue of $32.01 million for the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. Research analysts anticipate that Beta Bionics will post -2.05 EPS for the current fiscal year.

Insider Activity

In other news, insider Mark Hopman sold 36,870 shares of the stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $18.46, for a total value of $680,620.20. Following the completion of the sale, the insider directly owned 87,157 shares of the company’s stock, valued at $1,608,918.22. This represents a 29.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen Feider sold 6,675 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total transaction of $127,559.25. Following the sale, the chief financial officer owned 159,378 shares in the company, valued at $3,045,713.58. The trade was a 4.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 103,561 shares of company stock worth $1,962,504 over the last ninety days. Company insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd grew its position in shares of Beta Bionics by 1,075.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock worth $61,000 after purchasing an additional 1,818 shares in the last quarter. Legal & General Group Plc bought a new stake in Beta Bionics during the 2nd quarter valued at approximately $62,000. The Manufacturers Life Insurance Company purchased a new position in Beta Bionics in the 2nd quarter worth approximately $172,000. ProShare Advisors LLC purchased a new position in Beta Bionics in the 4th quarter worth approximately $217,000. Finally, Ieq Capital LLC purchased a new position in Beta Bionics in the 2nd quarter worth approximately $229,000.

More Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: The FDA cleared Beta Bionics’ Mint patch pump, expanding the company’s diabetes-device portfolio. A full U.S. launch is planned for the first quarter of 2027, potentially creating a second commercial growth driver alongside the iLet Bionic Pancreas. Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
• Positive Sentiment: Beta Bionics completed a public offering that generated $172.5 million in gross proceeds, including the underwriters’ full option exercise. The capital could support Mint commercialization, manufacturing expansion, research and development, and working capital, strengthening the balance sheet ahead of the launch. Beta Bionics Announces Closing of $172.5 Million Public Offering
• Neutral Sentiment: Recent insider sales included 30,779 shares sold by Mark Hopman and 2,650 shares sold by Mike Mensinger under pre-arranged Rule 10b5-1 plans. The transactions may attract attention, although they do not necessarily indicate a change in management’s outlook.
• Negative Sentiment: The offering involved millions of new shares and pre-funded warrants priced at $17.25, creating substantial potential dilution for existing shareholders and likely contributing to near-term selling pressure.
• Negative Sentiment: Beta Bionics faces a securities class action covering investors who purchased shares during much of 2025 and early 2026. Allegations involve the company’s disclosures concerning an FDA Form 483, a subsequent warning letter, quality-management issues and unreported customer complaints. The claims remain allegations, but the litigation adds legal, reputational and regulatory uncertainty. BBNX Shareholder Alert
• Negative Sentiment: Fiscal 2026 revenue guidance of $121 million to $126 million is below the roughly $133.9 million consensus estimate, signaling slower near-term growth than analysts expected.

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.